checkAd

    EQS-News  112  0 Kommentare Achiko AG looks back at pivotal year and reaffirms commitment to provide affordable and accurate Covid-19 testing solution

    EQS-News: Achiko AG / Key word(s): Miscellaneous
    Achiko AG looks back at pivotal year and reaffirms commitment to provide affordable and accurate Covid-19 testing solution

    23.12.2021 / 06:45


    Achiko AG looks back at pivotal year and reaffirms commitment to provide affordable and accurate Covid-19 testing solution

    - 2021 was a pivotal year for Achiko, marked by seminal developments and approvals

    - With AptameX(TM), Achiko launched an innovative DNA aptamer saliva-based rapid test for Covid-19 as an affordable and effective diagnostic for frequent mass testing

    - Second-generation of AptameX received full approval in Indonesia for five years

    - Focus on completing CE Mark and commercialization beyond Indonesia in 2022

    - In 2022, Achiko looks to further the Company's growth, proceeding to AptameX trials in other countries, completing its CE Mark registration to bring AptameX to other parts of Asia, the Middle East and northern Africa (MENA), and eastern Europe

    Zurich, 23 December 2021 - Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) ("Achiko", the "Company") looks back on a pivotal year. In the course of the last 12 months, the Company has created a unique healthtech ecosystem with its affordable, non-invasive Covid-19 rapid test AptameX(TM), integrated with Teman Sehat(TM) (Health Buddy), a digital passport solution that provides assurance services to communities enabling people to confidently go about their daily lives. The seminal launch of the ecosystem was made possible firstly by decisive internal development steps and the approval of the aptamer-based testing kit by the Indonesian authorities, followed by a rapid deployment on the ground as a fully functioning Covid-19 management system.

    Achiko's growth continues with the full approval of the second-generation of AptameX in Indonesia for five years and the negotiations now underway for sale at scale in various countries, empowering the Company to remain committed to provide diagnostic testing and pandemic management solutions and services amidst the continued threat of Covid-19 and its variants not only in Indonesia, but globally.

    Seite 1 von 5


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News Achiko AG looks back at pivotal year and reaffirms commitment to provide affordable and accurate Covid-19 testing solution EQS-News: Achiko AG / Key word(s): Miscellaneous Achiko AG looks back at pivotal year and reaffirms commitment to provide affordable and accurate Covid-19 testing solution 23.12.2021 / 06:45 Achiko AG looks back at pivotal year and reaffirms …